BBI:NSD-Brickell Biotech, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 0.70

Change

+0.02 (+2.72)%

Market Cap

USD 0.04B

Volume

2.61M

Average Target Price

USD 5.50 (+687.40%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Brickell Biotech, Inc., a clinical-stage pharmaceutical company, focuses on identifying, developing, and commercializing various prescription therapeutics for the treatment of debilitating skin diseases in the United States. The company's lead product candidate is sofpironium bromide that is in phase 3 clinical trial to treat patients with primary axillary hyperhidrosis. Its pipeline consists of potential novel therapeutics for hyperhidrosis and other prevalent dermatological conditions. Brickell Biotech, Inc. has a collaboration agreement with AnGes, Inc. for the development of a novel DNA vaccine candidate for COVID-19. The company was founded in 2009 and is headquartered in Boulder, Colorado.

Company Website : http://www.brickellbio.com

Address : 5777 Central Avenue, Boulder, CO, United States, 80301

Employees : 15

Fiscal Year End : December

Currency: USD

Country : USA

Technical Indicators

Beta : -0.17

52 Week High : 3.98

Short Ratio : 0.11

52 Week Low : 0.47

Shorted Shares : 263,918

200 Day Moving Average : 0.89

Shorted Shares Previous Month : 1,185,440

50 Day Moving Average : 0.62

Shares Held By Insiders : 20.78%

Shares Held by Institutions : 9.859999999999999%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-12-04 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna, Inc

-4.74 (-3.01%)

 USD62.38B N/A N/A
VRTX Vertex Pharmaceuticals Incorpo..

+1.45 (+0.64%)

 USD58.99B 22.23 17.39
REGN Regeneron Pharmaceuticals, Inc

-6.39 (-1.28%)

 USD53.23B 18.28 14.53
SGEN Seagen Inc

-0.93 (-0.52%)

 USD32.25B 68.04 62.62
BNTX BioNTech SE

+1.32 (+1.11%)

 USD29.16B -99,999.99 N/A
ALXN Alexion Pharmaceuticals, Inc

-0.55 (-0.45%)

 USD26.49B 28.09 26.92
RPRX Royalty Pharma plc

+0.68 (+1.61%)

 USD26.44B 22.60 9.98
GMAB Genmab A/S

+0.10 (+0.26%)

 USD24.77B 26.59 2.61
BGNE BeiGene, Ltd

+1.57 (+0.71%)

 USD20.63B N/A N/A
IMMU Immunomedics, Inc

N/A

 USD20.31B N/A N/A

ETFs Containing BBI

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -53.43% 12% F 5% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -53.43% 12% F 5% F
Trailing 12 Months  
Capital Gain -64.90% 7% F 3% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -64.90% 7% F 3% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -2.38% N/A N/A 31% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -2.38% N/A N/A 28% F
Risk Return Profile  
Volatility (Standard Deviation) 13.75% N/A N/A 83% B
Risk Adjusted Return -17.31% N/A N/A 25% F
Market Capitalization 0.04B 11% F 13% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 1.87 82% B- 59% F
Price / Cash Flow Ratio -1.01 13% F 61% D-
EV/EBITDA 0.04 86% B 98% A+
Management Effectiveness  
Return on Equity -132.17% 20% F 8% F
Return on Invested Capital -80.25% 35% F 12% F
Return on Assets -51.63% 15% F 4% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 0.11 96% A 95% A
Short Percent 0.51% 93% A 87% B+
Beta -0.17 96% A 97% A+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Underpriced compared to book value

The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Underpriced on free cash flow basis

The stock is trading low compared to its peers on a price to free cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector